Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

Autor: Cho, Byoung Chul, Chiu, Chao-Hua, Massarelli, Erminia, Buchschacher, Gary L., Goto, Koichi, Overbeck, Tobias R., Loong, Herbert H.F., Chee, Cheng E., Garrido, Pilar, Dong, Xiaorong, Fan, Yun, Lu, Shun, Schwemmers, Sven, Bordogna, Walter, Zeuner, Harald, Osborne, Stuart, John, Thomas

Publikováno v: In Lung Cancer February 2024 188

Using social exchange and equity theory to explore postgraduate student mentoring initiatives and academic faculty participation

Autor: Bordogna, Claudia M.

Publikováno v: International Journal of Mentoring and Coaching in Education, 2023, Vol. 12, Issue 2, pp. 128-144.

Externí odkaz: http://www.emeraldinsight.com/doi/10.1108/IJMCE-04-2022-0031

Paediatric critical COVID-19 and mortality in a multinational prospective cohort

Autor: Nofziger, Ryan, Ambati, Shashikanth, Kendirli, Tanil, Sanders, Ronald, Polikoff, Lee, Whelan, Siobhan, Camporesi, Anna, Francoeur, Conall, Castro, Francisca, Beltrán, Claudia, Pardo, Rosalba, Vega, Gonzalo, Yunge, Mauricio, Acevedo, Lorena, Ardila, Ivan Jose, Aranguiz, Diego, Dallefeld, Samantha, Alvarez-Olmos, MarthaI, Fernandez-Sarmiento, Jaime, Figueroa-Vargas, Arieth, Valencia-Benavides, Maribel, Roa, Juan David, Lasso-Palomino, Rubén, Franceschi, Alessia, Venthur, Carina, Gonzalez-Dambrauskas, Sebastian, Ampuero, Camila, Paco-Barral, Jhovana E., Tasayco-Muñoz, Jaime, Domínguez-Rojas, Jesús, Rafael-Patricio, Francisca, Pellegrini, Solana, Zuazaga, Marcela, Brusca, Silvana, Viera, Marisa, Aguilera-Avendano, Vladmir Ivan, Alejandro, F., Martínez, L., Thelma, E., Terán, M., Coronado-Lujan, Mariela, Castro-Mancilla, Fabiola, Diaz-Rubio, Franco, Cinquegrana, Karina, Sandoval, Alicia, Gonzalez, Andrea, Zamora, Marta, Lopez-Alarcon, Yurika, Slöcker-Barrio, María, Urbano-Villaescusa, Javier, Camacho, Humberto, Mazzillo, Liliana, Giraldo, Beatriz, Suarez, Pitas, Cespedes-Lesczinsky, Miguel, Castillo, Jorge Omar, Fabris, Juan Pablo, Paladino, Carolina, Sanabria, Silvia, Urena-Chavarría, Erika, Yock-Corrales, Adriana, Quispe, Gaudi, Munaico-Abanto, Manuel, Colombo, Miriam, Blanco, Ana Carola, Pineres-Olave, Byron Enrique, Carvajal-Veas, Ricardo, Correa, Patricia, Garcia-De-Jesus, Ricardo, Ferre, Arani, Pietroboni, Pietro, Mauricio-Cantillano, Edwin, Banegas-Pineda, Linda, Casson-Rodriguez, Nils, Cavagnaro, Agustin, Wegner, Adriana, Zemanate, Eliana, Beltran-Zuñiga, Emilce, Suarez, Maria Alejandra, Quiñonez, Deyanira, Valero, Leonardo, Repetur, Alejandra, Castellani, Pablo, Bordogna, Adriana, De-la-Hoz-Pastor, Alfredo, Obando-Belalcazar, Evelyn, Prout, Andrew, Jabornisky, Roberto, Wen, Andy, Coates, Bria, Watson, Christopher, Mack, Elizabeth, Hong, Jahee, Karsies, Todd, Pon, Steven, Dapul, Heda, Shein, Steven, Kangin, Murat, Vasquez-Hoyos, Pablo, Gertz, Shira, Ducharme-Crevier, Laurence, Harwayne-Gidansky, Ilana, Fonseca-Flores, Marisol, Nunez-Enriquez, Juan Carlos, Leon-Villanueva, Armando, Maria, Ledys, Muisyo, Teddy, Spaeder, Michael, Cantillano, Edwin Mauricio, Dominguez-Rojas, Jesus, Gurbanov, Anar, Mazzillo-Vega, Liliana, Shein, Steven L.

Publikováno v: In The Lancet Regional Health - Americas August 2022 12

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer

Autor: Joy C. Hsu, Felix Jaminion, Elena Guerini, Bogdana Balas, Walter Bordogna, Peter N. Morcos, Nicolas Frey

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1357-1370 (2021)

Abstract Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK‐positive non‐small cell lung cancer. Population pharmacokinetic (PK) models were developed for alectinib and its major active metabolite M4 using ph

Externí odkaz: https://doaj.org/article/3042761aeaaf42898d02ef39ffc33fc7